NCT02848079View on ClinicalTrials.gov

TAS-OX for Refractory Metastatic Colon Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

June 2, 2020

Study Completion Date

June 2, 2020

Conditions
Colorectal Neoplasms
Interventions
DRUG

combined TAS-102 and TAS-OX

Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.

Trial Locations (1)

06510

Yale Cancer Center, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT02848079 - TAS-OX for Refractory Metastatic Colon Cancer | Biotech Hunter | Biotech Hunter